HOSPITAL UNIVERSITARIO DE GETAFE
Departamento
GlaxoSmithKline (United Kingdom)
Londres, Reino UnidoPublicaciones en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (6)
2014
2013
-
Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: Results from the randomised, placebo-controlled avodart after radical therapy for Prostate Cancer Study (ARTS)
European Urology, Vol. 63, Núm. 5, pp. 779-787
-
Reply from authors re: Behfar Ehdaie, Karim A. Touijer. 5-Alpha reductase inhibitors in prostate cancer: From clinical trials to clinical practice. Eur Urol 2013;63:788-9: 5-Alpha reductase inhibitors in prostate cancer
European Urology
2004
-
Cardiovascular effects of the nitric oxide synthase inhibitor N G-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)
Critical Care Medicine, Vol. 32, Núm. 1, pp. 13-20
-
Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock
Critical Care Medicine, Vol. 32, Núm. 1, pp. 21-30
1999
-
Multi-center, randomized, placebo-controlled, double blind study of the nitric oxide synthase inhibitor 546c88: Effect on survival in patients with septic shock
Critical Care Medicine, Vol. 27, Núm. 1 SUPPL.